C07K 16/286
Against neuromediator receptors
Official title: {against neuromediator receptors, e.g. serotonin receptor, dopamine receptor}
C07K16/286 (Against neuromediator receptors) appears on 130 US grants and 235 published applications in this corpus.
Search patents in C07K- Granted patents
- 130
- Published applications
- 235
- Assignees
- 162
- Inventors
- 568
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 3 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 1 |
| 2002 | 5 | 9 |
| 2003 | 3 | 4 |
| 2004 | 1 | 3 |
| 2005 | 1 | 4 |
| 2006 | 3 | 5 |
| 2007 | 3 | 3 |
| 2008 | 2 | 3 |
| 2009 | 0 | 6 |
| 2010 | 0 | 7 |
| 2011 | 2 | 6 |
| 2012 | 2 | 6 |
| 2013 | 6 | 11 |
| 2014 | 2 | 6 |
| 2015 | 7 | 7 |
| 2016 | 3 | 9 |
| 2017 | 6 | 14 |
| 2018 | 4 | 12 |
| 2019 | 8 | 9 |
| 2020 | 6 | 12 |
| 2021 | 8 | 15 |
| 2022 | 6 | 16 |
| 2023 | 4 | 20 |
| 2024 | 11 | 14 |
| 2025 | 9 | 21 |
| 2026 | 8 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-Sortilin antibodies and use thereof29 Sep 2026US 12,747,294 B2H. Lundbeck A.S.
- GLP1R agonist NMDAR antagonist conjugates22 Sep 2026US 12,742,006 B2Københavns Universitet
- Anti-human neurotensin receptor 1 antibody and use thereof18 Aug 2026US 12,710,427 B2National Health Research Institutes
- Anti-human NR1 antibody derivative9 Jun 2026US 12,649,786 B2Arialys Therapeutics, Inc.
- Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease5 May 2026US 12,617,835 B2Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne)
- Pharmaceutical composition comprising foxm1 inhibitor and immune checkpoint inhibitor for preventing or treating cancer27 Aug 2026US 2026/0248881 A1National Cancer Center
- Antibodies for use in agrin-deficient disorders27 Aug 2026US 2026/0250423 A1argenx BV
- Methods for treating conditions using anti-nmda receptor antibodies13 Aug 2026US 2026/0234270 A1Lankenau Institute for Medical Research
- Method and reagents for the detection of an autoantibody13 Aug 2026US 2026/0235599 A1Centre National De La Recherche Scientifique
- Antibodies for treating neurological and neurovascular disorders6 Aug 2026US 2026/0226177 A1
Most cited
By later US patents
- DNA encoding human 5-HT.sub.1D receptors40US 5,155,218 ANeurogenetic Corporation · 1992
- Method for producing a mammalian G protein coupled glutamate receptor39US 5,385,831 AThe Board of Regents of the University of Washington · 1995
- Agonist antibodies38US 6,342,220 B12002
- Methods for treating cancer using GRM8 inhibitors29US 10,683,352 B1Flagship Pioneering Innovations V, Inc. · 2020
- Method and apparatus for collaborative system27US 8,316,104 B2California Institute of Technology · 2012